AzTrials
AzTrials

Thyroid Gland; NodeSWIDDICHNCT02378246

Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study

A study testing Iodine in people with Thyroid Gland; Node and Pregnancy, run by Göteborg University at 4 sites in Sweden.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

THE ULTIMATE GOAL of this project is to answer the question "In MILD IODINE DEFICIENCY (ID), should a tablet with vitamins and minerals, including 150 μg iodine/day be administered to pregnant women with a normal diet, to attain a normal cognitive development of the fetus or is there no cognitive deficit from mild ID… Read more about this study

Who is it for?
Ages 18 to 40 years, women only
What is being tested?
Iodine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,337 participants
Where
4 sitesSweden
Study dates
Nov 2012to Jun 2032
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Pregnant, week <13
  • Age 18-40 years
  • Intent of a full term pregnancy
  • Agreement of taking no iodide containing supplements during the study except for study supplement
  • Age 18-40 years
  • Agreeing not to take iodide containing supplements 1 week prior to the collecting of the samples.

Who cannot join

  • Known current thyroid disease
  • Risk factors for thyroid disease (history or heredity for thyroid, other autoimmune disease or symptoms of hypo-/hyperthyroidism) where the TSH is abnormal
  • Possibility to not attend to the protocol according to the investigator's opinion
  • Less than 6 months from previous pregnancy or lactating period
  • Vegan
  • CONTROL WOMEN
Show all 12Show fewer
  • Current thyroid disease
  • Risk factors for thyroid disease (history or heredity for thyroid or other autoimmune disease or symptoms of hypo-/hyperthyroidism) where the TSH is abnormal
  • Possibility to not attend to the protocol according to the investigator's opinion
  • Currently pregnant or lactating
  • Less than 6 months from previous pregnancy or lactating period
  • Vegans

Trial locations and contacts

4 sites in 1 country.

Sweden4 sites
  • Sahlgrenska University Hospital

    Gothenburg, 413 45

  • Linköping University Hospital

    Linköping, 581 85

  • Study site

    Skövde

  • Umeå Universitet, Department of Clinical Sciences

    Umeå, Västerbotten County, 901 85

Other trials in Sweden

About this study

Official title: The Importance of Iodine During Pregnancy for Future Brain Function : a Randomized Placebo-controlled Trial. Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study

THE ULTIMATE GOAL of this project is to answer the question "In MILD IODINE DEFICIENCY (ID), should a tablet with vitamins and minerals, including 150 μg iodine/day be administered to pregnant women with a normal diet, to attain a normal cognitive development of the fetus or is there no cognitive deficit from mild ID and no extra iodine is needed?". To answer this question, the investigators planned a randomized, placebo-controlled trial of micronutrient supplementation during pregnancy in Sweden (SWIDDICH) with the follow-up of childrens' COGNITIVE DEVELOPMENT at 18 months, 3.5, 7 and 14 years.

Iodine deficiency (ID) is associated with thyroid morbidity and, especially in children, with impaired cognitive development. Sweden introduced iodine fortification of table salt 1936 and mental retardation due to severe ID is eradicated. Is mild ID during pregnancy also eradicated? If not, is this of importance? A national study performed by the investigators in 2007 showed iodine sufficiency in general population, but there are no pregnancy data. Local studies have raised concerns for mild ID during pregnancy in Sweden and a trans-sectional national study is currently ongoing.

Read more

The burning question for Sweden and the whole world is: is mild ID during pregnancy of importance for the developing brain of the fetus? Two large observational studies have shown association between mild ID during pregnancy and lower verbal IQ or educational performance at school-aged children. The world needs a randomized placebo-controlled trial (RTC) comparing the cognitive outcome in children exposed to mild ID during fetal life with children exposed to normal iodine levels during fetal life.

Our HYPOTHESIS is that pregnant women in Sweden have mild ID and that children exposed to mild ID during fetal life have a lower cognitive development, compared to children to mothers taking daily tablet with vitamins and minerals, including 150 ug iodine during pregnancy.

The MAIN AIM of the SWIDDICH trial is to determine if children exposed to deficient micronutrition including mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation.

Read the detailed description

AIMS

  • To determine if children exposed to deficient micronutrition including mild iodine deficiency (ID) during fetal life achieve worse cognitive development compared to children exposed to normal iodine status reached by maternal iodine supplementation.
  • To investigate the interaction between iodine, selenium and iron, as components of the intervention.
  • To compare urinary iodine concentration (UIC), thyroglobulin (Tg), free tetraiodothyronine (FT4) and thyroid stimulating hormone (TSH) in pregnant women on daily tablet with vitamins and minerals, including 150 µg iodine or placebo
  • To compare milk iodine concentration (MIC) in colostrum, and TSH in the first 200 newborn children to pregnant women receiving daily tablet with vitamins and minerals, including 150 µg iodine or placebo

BACKGROUND Iodine deficiency increases the risk for hypothyroidism and goiter and during the pregnancy for abortion or cognitive and other abnormalities of the baby. According to the WHO recommendations, UIC during pregnancy should be 150-249 ug/L. In 2007 a national study showed iodine sufficiency in Swedish general population. It is debated whether or not iodine shall be given to pregnant women in iodine sufficient populations.

The research group started this randomized iodine intervention in pregnant women in 2012. The first hypothesis was that daily supplementation with a tablet with vitamins and minerals including 150 µg iodine is needed during pregnancy in Sweden in order to ensure normal iodine and thyroid hormone status in mothers and newborn children and that pregnant women in Sweden suffer from mild iodine deficiency (ID).

There is a substantial gap of knowledge with regards to whether mild ID during fetal life entails negative consequences on cognition. Two large observational studies have shown association between mild ID during pregnancy and lower IQ or educational performance in school-children. The only two randomized placebo-controlled trials (RCTs) studying mild ID in pregnancy were either too small for safe conclusions to be drawn ( Brucker-Davis et al, n=86), or did not manage to separate groups based on iodine levels (the MITCH study, Melse-Boonstra et al, n=839). The need for a RCT with sufficient sample size remains. This led the research team to form a second hypothesis within the trial: children exposed to deficient micronutrition including mild ID during fetal life have lower cognitive development compared to children to mothers taking a daily tablet with vitamins and minerals including150 ug iodine during pregnancy. The decision to expand the trial was made and the target number of participants to be recruited increased from 200 to 1275 in order to reach enough power to follow-up the childrens' cognitive development.

METHODS

Design

This is a prospective placebo-controlled trial of children whose mothers got iodine supplement 150 µg/day (a tablet with vitamins and minerals) or placebo (a multivitamin preparation without minerals) during pregnancy (week 10±2 until delivery). The target number participants during pregnancy is 1275 to enable sufficient power in the children follow-up (n=788). The main outcome is intelligence quotient (IQ) at 3.5 year of age. Cognitive development in children will be also assessed at 18 months, 7, and 14 years.

Pregnancy part

Pregnant women from more than ten maternity care centers in Sweden are randomized to daily receive a multivitamin tablet with minerals, including 150 µg iodine or placebo (multivitamin without iodine). The intervention starts at pregnancy week 8-12 and ends directly post-partum for the first 200 women and at pregnancy week 36±2weeks for the remaining participants. This time point may be adjusted to local circumstances, depending on when during the third trimester the routine visit at maternity care center takes place. Participants are included after the first visit by a midwife. Urine sample for UIC and U-creatinine, and blood sample for thyroid hormones, thyroid stimulating hormone (TSH), thyroglobuline (Tg) and thyroperoxidase antibodies (TPO-ab) are collected and a simple questionnaire is filled in at week 10±2 weeks of pregnancy and placebo/intervention is started. Selenium and iron are also measured. The same measurements are collected in week 25±1 week and week 36±2 weeks. Directly after delivery (within 5 days), MIC and UIC in the first 200 mother as well as UIC and TSH in their newborn child were collected and a simple questionnaire is filled in. Weight, length and APGAR in the child and pregnancy complications are registered. Blood is also frozen for future analyses and access to medical files is accepted.

In parallel 90 healthy female controls from Skaraborg area stratified for age and smoking habits are collected from a randomized sample attained by the Swedish Tax Agency. UIC, u-creatinine, FT4, TSH, Tg, TPO-ab, and samples to be frozen are collected and a questionnaire is filled in. Selenium and iron will be analyzed in blood sample from the first 200 pregnant women and from controls. The primary purpose for having a control population is to ascertain that the normal population in the area of Skaraborg is iodine sufficient.

Children follow-up

At 18 months ± 1 month psychomotor development is assessed by means of ASQ (Ages and Stages Questionnaire). At 3,5 years ± 2 months the IQ is measured (WPPSI-IV), behavior is assessed (CBCL questionnaire) and urine is collected for UIC measurement. At 7 years ± 3 months the following are assessed: IQ (WISC IV), motor development (Movement ABC), behavior (CBCL), symptoms related to attention deficit and hyperactivity disorder (ADHD, 5-15 Nordic questionnaire). Additionally, at 7 years ± 3 months urine is collected for UIC measurement, blood sample is taken for thyreoglobulin (Tg), thyroid hormones and deiodinases, and MRI of the brain is performed in a subsample. At 14 years ± 6 months all these, except for the Movement ABC, are repeated. On all occasions information on socio-economic status and other possible confounders are collected by means of questionnaires filled by parents and by children (14 years).

Being tested
Iodine, Placebo
Keywords
Iodine, Double-Blind Method, Randomized Controlled Tria, Cognitive Development
Medical subject headings
Thyroid Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IodineDietary supplement

  • PlaceboDietary supplement

Study groups in NCT02378246
Study groupRoleWhat they receive
Tablet with vitamins and minerals, containing 150 ug iodine, 1 tablet dailyExperimentalTable of contents: Vitamin B2 1.4 mg, Vitamin B12 15 µg, Iron 12 mg, Zinc 12 mg, Iodine 150 µg, Selenium 50 µg, Calcium 250 mg
Receives: Dietary Supplement: Iodine
Placebo: non-iodine containing multivitamin, 1 tablet dailyPlacebo comparatorTable of contents: Vitamin A 400 µg, Vitamin B1 1.4 mg, Vitamin B2 1.7 mg, Vitamin B6 1.8 mg, Vitamin B12 3 µg, Vitamin C 60 mg, Vitamin D 5 µg, Vitamin E 10 mg, Niacin 19 mg, Folic acid 200 µg
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intelligence quotient (IQ) at 3.5 years, WPPSI IV

    Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition; IQ with sub-domains

    Measured: when the child is at the age of 3,5 years ± 2 months

Secondary outcomes (50)
  1. Psychomotor development at 18 months, ASQ-3

    Ages \& Stages Questionnaire - Third Edition; a questionnaire filled in by parents

    Measured: when the child is at the age of 18 months ± 1 month

  2. Intelligence quotient (IQ) at 7 years, WISC IV

    Wechsler Intelligence Scale for Children - Fourth Edition; IQ with sub-domains

    Measured: when the child is at the age of 7 years ± 3 months

  3. Intelligence quotient (IQ) at 14 years, WISC IV

    Wechsler Intelligence Scale for Children - Fourth Edition; IQ with sub-domains

    Measured: when the child is at the age of 14 years ± 6 months

  4. Behavioral problems at 3.5 years, CBCL

    Child Behavior Checklist questionnaire filled in by parents

    Measured: when the child is at the age of 3,5 years ± 2 months

  5. Behavioral problems at 7 years, CBCL

    Child Behavior Checklist questionnaire filled in by parents

    Measured: when the child is at the age of 7 years ± 3 months

  6. Behavioral problems at 14 years, CBCL

    Child Behavior Checklist questionnaire filled in by parents

    Measured: when the child is at the age of 14 years ± 6 months

  7. ADHD-related problems at 7 years, FTF

    Nordic Questionnaire 5-15 (FTF) filled in by parents

    Measured: when the child is at the age of 7 years ± 3 months

  8. ADHD-related problems at 14 years, FTF

    Nordic Questionnaire 5-15 (FTF) filled in by parents

    Measured: when the child is at the age of 14 years ± 6 months

  9. Motor skills at 7 years, Movement ABC

    Movement ABC test performed by a physiotherapist

    Measured: when the child is at the age of 7 years ± 3 months

  10. Brain development at 7 years, MRI

    Magnetic Resonance Imaging; manual and automatic volumetry

    Measured: when the child is at the age of 7 years ± 3 months

  11. Brain development at 7 years, MRI

    Magnetic Resonance Imaging; manual and automatic volumetry

    Measured: when the child is at the age of 14 years ± 6 months

  12. Urinary iodine concentration (UIC) in the mother, 1st trimester

    Measured: 10±2 weeks (pregnancy)

  13. Urinary iodine concentration (UIC) in the mother, 2nd trimester

    Measured: 26±2 weeks (pregnancy)

  14. Urinary iodine concentration (UIC) in the mother, 3rd trimester

    Measured: 36±2 weeks (pregnancy)

  15. Thyreoglobulin concentration in serum, in the mother, 1st trimester

    Measured: 10±2 weeks (pregnancy)

  16. Thyreoglobulin in serum, in the mother, 2nd trimester

    Measured: 26±2 weeks (pregnancy)

  17. Thyreoglobulin in serum, in the mother, 3rd trimester

    Measured: 36±2 weeks (pregnancy)

  18. Thyroid stimulating hormon concentration in serum, in the mother, 1st trimester

    Measured: 10±2 weeks (pregnancy)

  19. Thyroid stimulating hormon concentration in serum, in the mother, 2nd trimester

    Measured: 26±2 weeks (pregnancy)

  20. Thyroid stimulating hormon concentration in serum, in the mother, 3rd trimester

    Measured: 36±2 weeks (pregnancy)

  21. Free thyroxine concentration in serum, in the mother, 1st trimester

    Measured: 10±2 weeks (pregnancy)

  22. Free thyroxine concentration in serum, in the mother, 2nd trimester

    Measured: 26±2 weeks (pregnancy)

  23. Free thyroxine concentration in serum, in the mother, 3rd trimester

    Free thyroxine concentration, serum

    Measured: 36±2 weeks (pregnancy)

  24. Anti-TPO in the mother, 1st trimester

    Thyroid peroxidase antibody titer, plasma

    Measured: 10±2 weeks (pregnancy)

  25. Anti-TPO in the mother, 2nd trimester

    Thyroid peroxidase antibody titer, plasma

    Measured: 26±2 weeks (pregnancy)

  26. Anti-TPO in the mother, 3rd trimester

    Thyroid peroxidase antibody titer, plasma

    Measured: 36±2 weeks (pregnancy)

  27. B12 in the mother, 1st trimester

    Vitamin B12, serum

    Measured: 10±2 weeks (pregnancy)

  28. B12 in the mother, 2nd trimester

    Vitamin B12, serum

    Measured: 26±2 weeks (pregnancy)

  29. B12 in the mother, 3rd trimester

    Vitamin B12, serum

    Measured: 36±2 weeks (pregnancy)

  30. Selenium in the mother, 1st trimester

    Selenium, serum

    Measured: 10±2 weeks (pregnancy)

  31. Selenium in the mother, 2nd trimester

    Selenium, serum

    Measured: 26±2 weeks (pregnancy)

  32. Selenium in the mother, 3rd trimester

    Selenium, serum

    Measured: 36±2 weeks (pregnancy)

  33. Iron in the mother, 1st trimester

    Iron, serum

    Measured: 10±2 weeks (pregnancy)

  34. Iron in the mother, 2nd trimester

    Iron, serum

    Measured: 26±2 weeks (pregnancy)

  35. Iron in the mother, 3rd trimester

    Iron, serum

    Measured: 36±2 weeks (pregnancy)

  36. Milk iodine concentration (MIC) in colostrum

    Measured: within 5 days after delivery

  37. Urinary iodine concentration (UIC) in the newborn

    Measured: within 5 days after delivery

  38. Urinary iodine concentration (UIC) in the mother

    Measured: within 5 days after delivery

  39. Urinary iodine concentration (UIC) at 3.5 years

    Measured: when the child is at the age of 3,5 years ± 2 months

  40. Urinary iodine concentration (UIC) at 7 years

    Measured: when the child is at the age of 7 years ± 3 months

  41. Urinary iodine concentration (UIC) at 14 years

    Measured: when the child is at the age of 14 years ± 6 months

  42. Thyroid stimulating hormone, dry blood spot (DBS), in the newborn

    Measured: within 5 days after delivery

  43. TSH at 7 years

    Thyroid stimulating hormone, dry blood spot (DBS)

    Measured: when the child is at the age of 7 years ± 3 months

  44. TSH at 14 years

    Thyroid stimulating hormone, dry blood spot (DBS)

    Measured: when the child is at the age of 14 years ± 6 months

  45. TG at 7 years

    Thyreoglobulin, dry blood spot (DBS)

    Measured: when the child is at the age of 7 years ± 3 months

  46. TG at 14 years

    Thyreoglobulin, dry blood spot (DBS)

    Measured: when the child is at the age of 14 years ± 6 months

  47. FT4 at 7 years

    Free thyroxine, dry blood spot (DBS)

    Measured: when the child is at the age of 7 years ± 3 months

  48. FT4 at 14 years

    Free thyroxine, dry blood spot (DBS)

    Measured: when the child is at the age of 14 years ± 6 months

  49. Deiodinases at 7 years

    Dry blood spot (DBS)

    Measured: when the child is at the age of 7 years ± 3 months

  50. Deiodinases at 14 years

    Dry blood spot (DBS)

    Measured: when the child is at the age of 14 years ± 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2015 (estimated)
  2. Study startNov 2012
  3. Primary completionJun 2029 (estimated)
  4. Study completionJun 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
1,337 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02378246
Sponsor's protocol ID
13031305
Acronym
SWIDDICH
Status last verified
Mar 2025
First submitted
19 Jan 2015
Last updated
26 Aug 2025
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided: This has not yet been discussed by the study group.

Publications

  • Manousou S, Eggertsen R, Hulthen L, Filipsson Nystrom H. A randomized, double-blind study of iodine supplementation during pregnancy in Sweden: pilot evaluation of maternal iodine status and thyroid function. Eur J Nutr. 2021 Sep;60(6):3411-3422. doi: 10.1007/s00394-021-02515-1. Epub 2021 Feb 23.

    PubMed 33620551
  • Manousou S, Johansson B, Chmielewska A, Eriksson J, Gutefeldt K, Tornhage CJ, Eggertsen R, Malmgren H, Hulthen L, Domellof M, Nystrom Filipsson H. Role of iodine-containing multivitamins during pregnancy for children's brain function: protocol of an ongoing randomised controlled trial: the SWIDDICH study. BMJ Open. 2018 Apr 10;8(4):e019945. doi: 10.1136/bmjopen-2017-019945.

    PubMed 29643159

Questions about this trial

What is this clinical trial studying?

A study testing Iodine in people with Thyroid Gland; Node and Pregnancy, run by Göteborg University at 4 sites in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 26 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intelligence quotient (IQ) at 3.5 years, WPPSI IV (time frame: when the child is at the age of 3,5 years ± 2 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02378246, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in